Hetero Healthcare and Enzene Launch Perzea: Affordable Pertuzumab Biosimilar Expands Breast Cancer Treatment Access in India

Share via:


Hyderabad (Telangana) [India], September 25: In a landmark initiative to expand affordable breast cancer treatment in India, Hetero Healthcare Limited has announced the launch of Perzea, its most cost-effective biosimilar of Pertuzumab. Developed through a semi-exclusive collaboration with Enzene Biosciences Limited, this breakthrough aims to reduce the economic barriers faced by thousands of HER2-positive breast cancer patients.

Bringing Advanced Cancer Care Within Reach
Pertuzumab, a monoclonal antibody, is globally recognised as…



Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We StartupNews.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.

Popular

More Like this

Hetero Healthcare and Enzene Launch Perzea: Affordable Pertuzumab Biosimilar Expands Breast Cancer Treatment Access in India


Hyderabad (Telangana) [India], September 25: In a landmark initiative to expand affordable breast cancer treatment in India, Hetero Healthcare Limited has announced the launch of Perzea, its most cost-effective biosimilar of Pertuzumab. Developed through a semi-exclusive collaboration with Enzene Biosciences Limited, this breakthrough aims to reduce the economic barriers faced by thousands of HER2-positive breast cancer patients.

Bringing Advanced Cancer Care Within Reach
Pertuzumab, a monoclonal antibody, is globally recognised as…



Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We StartupNews.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.

Website Upgradation is going on for any glitch kindly connect at office@startupnews.fyi

More like this

Apple’s first foldable iPhone leaks suggest book-style design and...

Apple’s long-rumoured foldable iPhone appears to be taking...

The Dollar Is Facing an End to Its Dominance

2026 will be the year when US dollar dilution—the...

The Right Type of Collagen That’s Best for Your...

Collagen is all the hype if you pay close...

Popular